Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records.
暂无分享,去创建一个
Pedro L. Teixeira | F. Harrell | E. Benjamin | P. Ellinor | D. Roden | J. Denny | S. Heckbert | K. Moons | K. Moons | Á. Alonso | D. Darbar | Hua Xu | M. Shoemaker | A. Shintani | A. Bian | B. Parvez | Matthew J. Kolek | A. Graves | Meng Xu | P. L. Teixeira | M. B. Shoemaker | Babar Parvez
[1] N. Roetker,et al. Prediction of Atrial Fibrillation in a Racially Diverse Cohort: The Multi‐Ethnic Study of Atherosclerosis (MESA) , 2016, Journal of the American Heart Association.
[2] R. Luben,et al. Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort , 2015, European journal of preventive cardiology.
[3] Lowering blood pressure in patients with diabetes--reply. , 2015, JAMA.
[4] C. Murray,et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.
[5] Kevin B. Johnson,et al. Electronic health record design and implementation for pharmacogenomics: a local perspective , 2013, Genetics in Medicine.
[6] Melissa A. Basford,et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. , 2013, Journal of the American Medical Informatics Association : JAMIA.
[7] David D. McManus,et al. Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium , 2013, Journal of the American Heart Association.
[8] Hongfang Liu,et al. A Study of Transportability of an Existing Smoking Status Detection Module across Institutions , 2012, AMIA.
[9] Melissa A. Basford,et al. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping , 2012, Clinical pharmacology and therapeutics.
[10] G. Lip,et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. , 2012, Journal of the American College of Cardiology.
[11] H. Calkins. Catheter ablation to maintain sinus rhythm. , 2012, Circulation.
[12] M. Woodward,et al. Risk prediction models: II. External validation, model updating, and impact assessment , 2012, Heart.
[13] Suzette J. Bielinski,et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study , 2012, J. Am. Medical Informatics Assoc..
[14] S. Johnston,et al. Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States , 2011, Circulation. Cardiovascular quality and outcomes.
[15] Yu Wang,et al. The Role of Renin–Angiotensin System Blockade Therapy in the Prevention of Atrial Fibrillation: A Meta‐Analysis of Randomized Controlled Trials , 2010, Clinical pharmacology and therapeutics.
[16] Son Doan,et al. Integrating existing natural language processing tools for medication extraction from discharge summaries , 2010, J. Am. Medical Informatics Assoc..
[17] M. Böhm,et al. Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition , 2010 .
[18] Melissa A. Basford,et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. , 2010, American journal of human genetics.
[19] Son Doan,et al. Application of information technology: MedEx: a medication information extraction system for clinical narratives , 2010, J. Am. Medical Informatics Assoc..
[20] D. Levy,et al. Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop , 2009, Circulation.
[21] Monique M. B. Breteler,et al. The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.
[22] D. Roden,et al. Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.
[23] V. Gudnason,et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. , 2007, American journal of epidemiology.
[24] N. Cook. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.
[25] Stephen S. Cha,et al. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.
[26] L. Fried,et al. Thyroid status, cardiovascular risk, and mortality in older adults. , 2006, JAMA.
[27] Thomas Lavergne,et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. , 2004, American heart journal.
[28] G. Jensen,et al. Rising Rates of Hospital Admissions for Atrial Fibrillation , 2003, Epidemiology.
[29] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[30] B. Horne,et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. , 2002, Journal of the American College of Cardiology.
[31] Simon Stewart,et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.
[32] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[33] D. Singer,et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.
[34] Mark E. Hill,et al. The Social Security Administration's Death Master File: the completeness of death reporting at older ages. , 2001, Social security bulletin.
[35] F. Nieto,et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .
[36] D S Bell,et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. , 2000, New England Journal of Medicine.
[37] O. Benavente,et al. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.
[38] J. Sowers,et al. Diabetes and cardiovascular disease. , 1999, Diabetes care.
[39] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[40] D. Levy,et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.
[41] R B D'Agostino,et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. , 1998, Archives of internal medicine.
[42] F A Mathewson,et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.
[43] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[44] J. Blumenthal,et al. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. , 1994, The American journal of cardiology.
[45] N J Wald,et al. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.
[46] R. Kronmal,et al. The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.
[47] Aric Invest. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators , 1989 .
[48] A. Folsom,et al. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.
[49] D J Spiegelhalter,et al. Probabilistic prediction in patient management and clinical trials. , 1986, Statistics in medicine.
[50] F. Harrell,et al. Evaluating the yield of medical tests. , 1982, JAMA.
[51] W. Kannel,et al. Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.
[52] W. Kannel,et al. The Framingham Offspring Study. Design and preliminary data. , 1975, Preventive medicine.
[53] W. Kannel,et al. Relation of Body Weight to Development of Coronary Heart Disease: The Framingham Study , 1967, Circulation.
[54] W. Kannel,et al. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.